Clinical Trials Browser

Phase 2 × ribociclib × 1 year × Clear all

NCT02934568 2026-04-16

Ribociclib (LEE011) Rollover Study for Continued Access

Phase 2 Active not recruiting

Other solid neoplasm

Continued Access to Study Treatment(s), Cancers With a Mass, Bulky Tumor, Nodule, Lump, Advanced Cancer, Advanced Solid Tumors, Advanced Solid Malignancies

NCT04920708 2026-04-14

FAIM

Phase 2 Active not recruiting

Breast Neoplasms

NCT05467891 2026-04-08

RaPhLRR

Phase 2 Recruiting

Locoregional Recurrence

NCT07405801 2026-04-06

A Phase II Study Evaluating the Efficacy and Safety of Inavolisib Plus Ribociclib Plus Fulvestrant Versus Placebo Plus Ribociclib Plus Fulvestrant in Participants With Advanced Breast Cancer

Phase 2 Recruiting

Breast Neoplasms

NCT07054190 2026-03-31

A Study to Test Inavolisib Treatments in Participants With Early-Stage, PIK3CA-Mutated Breast Cancer

Phase 2 Recruiting

Breast Neoplasms

NCT05843253 2026-03-20

Study of Ribociclib and Everolimus in HGG and DIPG or Ribociclib and Temozolomide in DHG, H3G34-mutant

Phase 2 Recruiting

Diffuse Intrinsic Pontine Glioma, Astrocytoma, Brain Neoplasms, Glioblastoma, Glioma

NCT04417621 2026-03-12

Study of Efficacy and Safety of LXH254 Combinations in Patients With Previously Treated Unresectable or Metastatic Melanoma

Phase 2 Active not recruiting

Melanoma

NCT02712723 2026-03-11

FELINE

Phase 2 Active not recruiting

121 enrolled 9 charts

Breast Neoplasms

NCT02645149 2026-02-27

Match Mel

Phase 2 Completed

Melanoma

NCT03008408 2026-02-11

A Phase II, Two-Arm Study of Everolimus and Letrozole, +/- Ribociclib (Lee011) in Patients With Advanced or Recurrent Endometrial Carcinoma

Phase 2 Active not recruiting

Endometrial Neoplasms

NCT05826964 2026-01-13

Levels of Circulating Tumor DNA as a Predictive Marker for Early Switch in Treatment for Patients With Metastatic (Stage IV) Breast Cancer

Phase 2 Active not recruiting

Breast Neoplasms

NCT06849947 2025-12-24

Fulvestrant With Ribociclib Versus Physician's Choice Treatments Recurred After Completion of Adjuvant Cyclin-Dependent Kinase 4/6 Inhibitors in HR+, HER2- Metastatic Breast Cancer

Phase 2 Not yet recruiting

Breast Cancer Metastatic

NCT03673124 2025-12-23

Ribociclib and Letrozole Treatment in Ovarian Cancer

Phase 2 Active not recruiting

51 enrolled 19 charts

Cystadenocarcinoma, Serous

NCT03285412 2025-12-22

LEADER

Phase 2 Active not recruiting

Breast Neoplasms

NCT06409390 2025-12-04

Sequential Therapies Modeled on Evolutionary Dynamics for Breast Cancer

Phase 2 Recruiting

Breast Neoplasms

NCT04116541 2025-11-21

MegaMOST

Phase 2 Recruiting

Neoplasm Metastasis

NCT03671330 2025-10-31

Efficacy and Safety of Ribociclib in Pre- and Postmenopausal Chinese Women With HR Positive, HER2-negative, Advanced Breast Cancer.

Phase 2 Completed

Breast Neoplasms

NCT06062498 2025-10-20

Elacestrant vs Elacestrant Plus a CDK4/6 Inhibitor in Patients With ERpositive/HER2-negative Advanced or Metastatic Breast Cancer

Phase 2 Recruiting

Breast Neoplasms

NCT03822468 2025-10-16

AMALEE

Phase 2 Completed

376 enrolled 17 charts

Breast Neoplasms

NCT07195227 2025-10-02

CADILLAC

Phase 2 Not yet recruiting

Breast Neoplasms

NCT03283384 2025-09-19

NEOLBC

Phase 2 Active not recruiting

Breast Neoplasms

NCT05900206 2025-09-02

ARIADNE

Phase 2 Recruiting

Breast Neoplasms

NCT05625087 2025-08-20

SAFIR 03

Phase 2 Active not recruiting

Breast Neoplasms

NCT06953882 2025-07-14

SELECT

Phase 2 Recruiting

HER2 Negative Breast Cancer